UPF0764 protein C16orf89 homolog Antibody

What is UPF0764 protein C16orf89 homolog?

UPF0764 protein C16orf89 homolog is a protein encoded by the C16orf89 gene (Chromosome 16 open reading frame 89) in humans, with homologs present across multiple species. The "UPF" designation (Uncharacterized Protein Family) indicates that this protein's function remains largely uncharacterized. Despite limited functional characterization, the protein's conservation across diverse species—from mammals to marine invertebrates—suggests it likely serves an important biological role .

How conserved is C16orf89 across species?

C16orf89 demonstrates remarkable evolutionary conservation, with homologs identified in diverse species including:

• Mammals: Sus scrofa (pig), Ursus maritimus (polar bear), Odocoileus virginianus texanus (white-tailed deer)

• Marine invertebrates: Exaiptasia pallida (sea anemone)

This cross-species conservation pattern suggests the protein may perform fundamental cellular functions. The protein is referred to as "UPF0764 protein C16orf89 homolog" in non-human species, with various chromosomal locations depending on the species .

What isoforms of C16orf89 have been identified?

Multiple isoforms of C16orf89 have been documented across species. For example:

• In Sus scrofa (pig): Three identified isoforms (X1, X2, X3)

  • XP_003354677.1 (isoform X1)

  • XP_013851122.1 (isoform X2)

  • XP_013851123.1 (isoform X3)

• In Ursus maritimus (polar bear): Three identified isoforms

  • XP_008695086.1 (isoform X1)

  • XP_008695087.1 (isoform X2)

  • XP_008695088.1 (isoform X3)

These multiple isoforms suggest potential tissue-specific or function-specific expression patterns that researchers should consider when designing experiments .

What antibodies are available for C16orf89 detection?

Several validated antibodies are available for C16orf89 detection with different applications:

Note that the majority of available antibodies are polyclonal, and most have been validated primarily for immunohistochemistry (IHC) applications, with fewer options validated for Western blotting (WB) .

How should researchers validate C16orf89 antibodies?

For rigorous C16orf89 antibody validation, researchers should employ multiple approaches:

• Positive and negative controls:

  • Positive: Tissue/cells known to express C16orf89

  • Negative: Tissue/cells with C16orf89 knockdown or knockout

• Cross-validation of techniques:

  • Compare IHC results with Western blot, immunofluorescence, or mass spectrometry data

  • Use at least two different antibodies targeting different epitopes

• Specificity tests:

  • Peptide competition assays using the immunizing peptide

  • Pre-adsorption controls to confirm specificity

  • Molecular weight verification in Western blotting

• Expression pattern verification:

  • Confirm localization patterns match known biology

  • Verify across multiple tissue types when possible .

What technical considerations affect C16orf89 antibody performance?

Several technical factors can significantly impact C16orf89 antibody performance:

• Fixation methods: Formalin fixation may mask epitopes; antigen retrieval optimization is critical for IHC applications.

• Dilution optimization: A dilution series (typically 1:100 to 1:10,000) should be tested for each application to determine optimal signal-to-noise ratio.

• Blocking procedures: BSA or normal serum from the species of secondary antibody origin can minimize non-specific binding.

• Detection methods: For low expression targets, consider signal amplification systems like tyramide signal amplification.

• Sample preparation: For Western blot applications, optimize lysis buffers and protein extraction protocols to ensure complete solubilization of the target protein .

What is the optimal protocol for immunohistochemical detection of C16orf89?

Based on validated antibody applications, the following protocol is recommended for C16orf89 IHC:

• Tissue preparation:

  • Fix tissues in 10% neutral-buffered formalin

  • Paraffin-embed, section at 5-μm thickness

  • Mount on positively charged glass slides

• Antigen retrieval:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Boil for 20 minutes, then cool gradually

• Blocking and antibody incubation:

  • Block with 5% normal serum (from secondary antibody species)

  • Incubate with primary antibody (1:1,000 dilution for most C16orf89 antibodies)

  • Incubate overnight at 4°C

• Detection and visualization:

  • Use appropriate HRP-conjugated secondary antibody

  • Visualize with ImmPACT NovaRED Substrate Kit or DAB

  • Counterstain with hematoxylin

  • Examine under light microscope at 4× and 40× objectives .

How can researchers optimize Western blot protocols for C16orf89?

For optimal Western blot detection of C16orf89, researchers should:

• Sample preparation:

  • Use RIPA or NP-40 lysis buffer with protease inhibitors

  • Sonicate briefly to ensure complete protein extraction

  • Clear lysates by centrifugation (14,000×g for 15 min at 4°C)

• Gel electrophoresis and transfer:

  • Use 10-12% SDS-PAGE gels

  • Load 20-50 μg protein per lane

  • Transfer to PVDF membranes (preferred over nitrocellulose for this protein)

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk in TBST

  • Use STJ195460 antibody (1:1000 dilution), optimized for WB

  • Incubate overnight at 4°C

• Detection and visualization:

  • Use HRP-conjugated secondary antibodies

  • Visualize with enhanced chemiluminescence (ECL) substrate

  • Compare band intensity to β-actin for normalization

• Troubleshooting tips:

  • If bands are weak, increase protein loading or reduce antibody dilution

  • For multiple bands, optimize primary antibody concentration or consider using a monoclonal antibody if available .

How should researchers approach protein-protein interaction studies for C16orf89?

For investigating C16orf89 protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Pre-clean cell lysates with protein G-agarose (4°C for 1 hour)

  • Incubate with anti-C16orf89 antibody overnight at 4°C

  • Add protein G-agarose, incubate for 3 hours at 4°C

  • Wash precipitates and analyze by Western blot for potential interaction partners

• Proximity ligation assay (PLA):

  • Use for in situ detection of protein interactions

  • Requires two primary antibodies from different species

  • Visualize interactions as fluorescent dots by microscopy

• Bait-and-prey approaches:

  • Consider yeast two-hybrid or BioID approaches

  • For mammalian systems, use CRISPR-Cas9 to tag endogenous C16orf89 with GFP or FLAG

  • Perform pull-down experiments followed by mass spectrometry

• Controls and validation:

  • Use IgG isotype controls

  • Validate interactions using reciprocal Co-IP

  • Confirm interactions using orthogonal methods .

How can transcriptomic approaches complement protein studies of C16orf89?

Transcriptomic analysis can provide valuable insights into C16orf89 regulation:

• RNA sequencing workflow:

  • Extract total RNA using validated column-based methods

  • Perform quality control using Bioanalyzer or TapeStation

  • Generate cDNA libraries using random primers and reverse transcription

  • Sequence using appropriate platform (Illumina, Ion Torrent, etc.)

• Bioinformatic analysis strategies:

  • For species with reference genomes: Use reference-based assembly

  • For non-model organisms: Employ de novo assembly

  • Follow established workflows for transcriptome assembly, gene annotation, differential expression analysis, and experimental validation

• Integration with proteomic data:

  • Compare transcript and protein abundance to identify post-transcriptional regulation

  • Use pathway analysis tools to contextualize findings within biological networks

  • Consider tissue-specific expression patterns when interpreting results .

What are the challenges in studying evolutionarily conserved proteins like C16orf89?

Researchers face several challenges when investigating conserved proteins like C16orf89:

• Cross-reactivity considerations: Antibodies may cross-react with homologs from different species. When studying C16orf89 in non-human models, researchers should validate antibody specificity against the species-specific sequence.

• Functional redundancy: Highly conserved proteins often have functional redundancy, making single-gene knockout studies challenging to interpret. Consider combinatorial approaches targeting multiple family members.

• Species-specific differences: Despite conservation, subtle species-specific differences in:

  • Post-translational modifications

  • Interaction partners

  • Subcellular localization

  • Regulation mechanisms

  These differences necessitate careful interpretation when translating findings across species .

• Experimental design considerations:

  • Use multiple species when possible to strengthen evolutionary insights

  • Consider complementary functional assays beyond expression studies

  • Employ comparative genomics to identify conserved regulatory elements

How might single-cell approaches advance our understanding of C16orf89?

Single-cell methodologies offer powerful approaches for C16orf89 characterization:

• Single-cell RNA sequencing (scRNA-seq):

  • Reveals cell type-specific expression patterns

  • Can identify rare cell populations expressing C16orf89

  • Enables trajectory analysis to understand dynamic regulation

• Single-cell proteomics:

  • Emerging mass cytometry (CyTOF) or imaging mass cytometry approaches

  • Requires development of metal-tagged antibodies for C16orf89

  • Can correlate C16orf89 expression with cellular phenotypes

• Spatial transcriptomics/proteomics:

  • Technologies like Visium, MERFISH, or imaging mass spectrometry

  • Can map C16orf89 expression in tissue context

  • Critical for understanding function in complex tissues .

What experimental approaches can elucidate the biological function of C16orf89?

To determine C16orf89 function, researchers should consider:

• Loss-of-function studies:

  • CRISPR-Cas9 knockout/knockdown

  • siRNA/shRNA approaches

  • Assess phenotypic consequences across multiple cell types

• Gain-of-function studies:

  • Overexpression of tagged constructs

  • Inducible expression systems

  • Domain-specific mutagenesis to identify functional regions

• Interactome mapping:

  • Proximity labeling (BioID, APEX)

  • IP-MS approaches

  • Yeast two-hybrid screening

• Structural biology approaches:

  • X-ray crystallography or cryo-EM

  • NMR spectroscopy for dynamic regions

  • In silico modeling based on homology .